|[July 02, 2014]
Batu Biologics Appoints Biotechnology Industry Veteran, Dr. Alan Lewis, to Scientific Advisory Board
SAN DIEGO --(Business Wire)--
Batu Biologics announced today the appointment of Dr. Alan Lewis to the
company's Scientific Advisory Board, an experienced industry veteran
with over 37 years of experience as an executive in life sciences. Dr.
Lewis spent 15 years at the pharmaceutical company Wyeth-Ayerst, where
he was Vice President of Research, leading translational research
efforts in diabetes, CNS, cardiovascular, inflammatory, allergy and bone
metabolism diseases. He later became the CEO of Signal Pharmaceuticals,
a company focusing on small-molecule drug discovery and development,
which was eventually acquired by Celgene in 2010. Subsequent to his
employment as President of Celgene, Dr. Lewis had several successful
business ventures including raising $27 million as CEO of Novocell,
becoming the CEO of the Juvenile Diabetes Research Foundation, and
raising over $45 million as CEO of Ambit.
"The Batu Biologics Team is extremely excited to have Dr. Alan Lewis on
board to assist with the development and commercialization of ValloVaxTM,"
said Samuel C. Wagner, President and CEO of Batu Biologics. "We believe
Dr. Lewis' extensive experience in strategic development as well as his
astonishing track record will not only help facilitate the expedited
growth of our company, but also bring many new eyes to our cause."
"It is my honor to continue working with Dr. Lwis. In our previous work
at Medistem Inc, the recruitment of Dr. Lewis was a pivotal event that
led to the $26 million dollar acquisition of our company. We anticipate
expanding on this success at Batu Biologics," said Thomas Ichim,
Chairman of Batu Biologics and former President of Medistem Inc.
"The concept of immunologically targeting the 'Achilles Heel' of the
tumor, by inducing the immune response to kill blood vessels that feed
the tumor, is novel and promising. I look forward to working with Mr.
Wagner and the team at Batu Biologics at developing a new weapon in the
fight against cancer," said Dr. Lewis.
Earlier this month, Batu Biologics announced efforts to raise $100,000
through donation-based crowd funding to support completion of the
company's preclinical research in preparation of the filing of an
Investigational New Drug (IND) application to the FDA. Link to the
About Batu Biologics
Founded in 2013, Batu Biologics is a preclinical biopharmaceutical
company focusing on developing and commercializing allogeneic cell
therapies in the area of immune modulation. The company's products are
centered around the idea of creating or breaking immune tolerance. The
company is currently in the preclinical stages of drug development for
its two flagship products: Immstem and Vallovax. With the recent
successes of immunotherapy in a variety of tumors, Batu Biologics
believes there is an increasing unmet need for non-toxic immune
modulators that can augment efficacy of existing therapeutics. Our team
is motivated to bring novel therapeutics to the forefront of medical
research that use the power of the body's own immune system to extend
life expectancy. Batu Biologics has filed two provisional patents in the
field of cancer immunotherapy and plans to significantly expand its IP
9255 Towne Centre Drive
Diego, CA (News - Alert) 92121
Janssen Research and Development
San Diego, CA 92121
[ Back To Technology News's Homepage ]